RenovoRx Reports Third Quarter 2024 Financial Results and Operational Highlights
RenovoRx reported Q3 2024 financial results with $9.6 million in cash as of September 30, sufficient to fund operations through next interim analysis of its Phase III TIGeR-PaC clinical trial and RenovoCath commercialization efforts. The company reported a net loss of $2.5 million, with R&D expenses at $1.7 million and G&A expenses at $1.2 million. RenovoCath, their FDA-cleared delivery system, is advancing towards commercialization with increased production and potential revenue generation in 2025. The Phase III trial for locally advanced pancreatic cancer is progressing towards completion of patient enrollment, expected in first half of 2025.
RenovoRx ha riportato i risultati finanziari del terzo trimestre 2024, con 9,6 milioni di dollari in contante al 30 settembre, sufficienti a finanziare le operazioni fino alla prossima analisi intermedia del suo trial clinico TIGeR-PaC di Fase III e gli sforzi di commercializzazione di RenovoCath. L'azienda ha registrato una perdita netta di 2,5 milioni di dollari, con spese di R&D pari a 1,7 milioni di dollari e spese generali e amministrative pari a 1,2 milioni di dollari. RenovoCath, il loro sistema di somministrazione approvato dalla FDA, sta avanzando verso la commercializzazione con un aumento della produzione e la potenziale generazione di entrate nel 2025. Il trial di Fase III per il cancro pancreatico localmente avanzato sta progredendo verso il completamento dell'arruolamento dei pazienti, previsto per la prima metà del 2025.
RenovoRx informó los resultados financieros del tercer trimestre de 2024, con 9,6 millones de dólares en efectivo al 30 de septiembre, suficientes para financiar las operaciones hasta el próximo análisis intermedio de su ensayo clínico TIGeR-PaC de Fase III y los esfuerzos de comercialización de RenovoCath. La empresa reportó una pérdida neta de 2,5 millones de dólares, con gastos de I+D de 1,7 millones de dólares y gastos generales y administrativos de 1,2 millones de dólares. RenovoCath, su sistema de entrega aprobado por la FDA, avanza hacia la comercialización con un aumento en la producción y la potencial generación de ingresos en 2025. El ensayo de Fase III para el cáncer pancreático localmente avanzado está avanzando hacia la finalización del reclutamiento de pacientes, que se espera en la primera mitad de 2025.
RenovoRx는 2024년 3분기 재무 결과를 보고하며, 9월 30일 기준으로 960만 달러의 현금을 보유하고 있어 TIGeR-PaC 임상 시험의 다음 중간 분석 및 RenovoCath 상용화를 위한 운영 자금을 충분히 확보하고 있습니다. 회사는 250만 달러의 순손실을 기록했으며, R&D 비용은 170만 달러, 일반 관리비는 120만 달러입니다. RenovoCath, FDA에서 승인한 전달 시스템은 2025년의 증가된 생산 및 잠재적 수익 창출과 함께 상용화를 향해 나아가고 있습니다. 진행 중인 국소 진행성 췌장암에 대한 3상 시험은 2025년 상반기 환자 등록 완료가 예상되고 있습니다.
RenovoRx a rapporté des résultats financiers pour le troisième trimestre 2024, avec 9,6 millions de dollars en espèces au 30 septembre, suffisants pour financer les opérations jusqu'à la prochaine analyse intermédiaire de son essai clinique TIGeR-PaC de Phase III et les efforts de commercialisation de RenovoCath. L'entreprise a enregistré une perte nette de 2,5 millions de dollars, avec des dépenses de R&D s'élevant à 1,7 million de dollars et des frais généraux administratifs de 1,2 million de dollars. RenovoCath, leur système de délivrance approuvé par la FDA, avance vers la commercialisation avec une production accrue et un potentiel de génération de revenus en 2025. L'essai de Phase III pour le cancer du pancréas avancé localement progresse vers l'achèvement de l'inscription des patients, prévu pour la première moitié de 2025.
RenovoRx hat die Finanzergebnisse für das dritte Quartal 2024 gemeldet, mit 9,6 Millionen Dollar in bar zum 30. September, die ausreichen, um die Betriebe bis zur nächsten Zwischenanalyse der TIGeR-PaC-Phase-III-Studie und der Commercialisierung von RenovoCath zu finanzieren. Das Unternehmen meldete einen Nettoverlust von 2,5 Millionen Dollar, mit F&E-Ausgaben von 1,7 Millionen Dollar und allgemeinen Verwaltungskosten von 1,2 Millionen Dollar. RenovoCath, ihr von der FDA genehmigtes Abgabesystem, schreitet mit einer erhöhten Produktion und potenziellen Einnahmequellen im Jahr 2025 in Richtung Kommerzialisierung voran. Die Phase-III-Studie für lokal fortgeschrittenen Bauchspeicheldrüsenkrebs nähert sich dem Abschluss der Patientenrekrutierung, die in der ersten Hälfte von 2025 erwartet wird.
- FDA-cleared RenovoCath delivery system moving towards commercialization with potential revenue in 2025
- $9.6 million cash position sufficient for next interim analysis and commercialization efforts
- Increased production of RenovoCath supplies through manufacturing partner Medical Murray
- Expansion of clinical trial sites with University of Nebraska Medical Center joining TIGeR-PaC study
- Reduction in G&A expenses by $0.2 million compared to previous year
- Net loss increased to $2.5 million from $1.4 million in Q3 2023
- Anticipated increase in R&D expenses due to manufacturing costs and clinical trial advancement
- Expected increase in G&A expenses for commercialization activities
Insights
RenovoRx's Q3 results reveal a strategic positioning with
The company's dual-track strategy focuses on commercializing RenovoCath while advancing their Phase III TIGeR-PaC trial. The increased production commitment with Medical Murray signals confidence in market demand, though revenue generation isn't expected until 2025. With a market cap of
The pivotal Phase III TIGeR-PaC trial's progression towards its next interim analysis represents a significant clinical milestone. The addition of University of Nebraska Medical Center as a trial site is strategically important given their high pancreatic cancer patient volume, which should accelerate enrollment completion targeted for H1 2025.
The publication in The Oncologist® of early-stage clinical data validates the TAMP approach for locally advanced pancreatic cancer treatment. The RenovoCath delivery system's FDA clearance for vessel occlusion and chemotherapeutic drug infusion provides multiple revenue opportunities across oncology and interventional radiology applications, though market adoption rates remain uncertain.
Near-Term Revenue Potential with Commercialization Plan for FDA-Cleared RenovoCath® Delivery System in Both Direct and Commercial Partner Channels
Renowned Clinical Oncology Sites Participating in Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial; Trial Moving Towards Next Interim Analysis and Full Enrollment
As of September 30, 2024, the Company had
LOS ALTOS, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences company developing novel targeted oncology therapies and offering RenovoCath, a novel, FDA-cleared local drug-delivery platform, today announced its financial results and operational highlights for the third quarter ended September 30, 2024.
“We made significant progress in the third quarter of 2024 towards our goal of patient enrollment completion of our pivotal Phase III TIGeR-PaC clinical trial in locally advanced pancreatic cancer (LAPC), which is expected in the first half of 2025,” said Shaun Bagai, CEO of RenovoRx. “In parallel, we have made important headway on commercialization plans for our FDA-cleared RenovoCath delivery system, creating the potential for near-term revenue generation.”
Mr. Bagai added, “As part of our evolving commercialization strategy plans, we have increased production of RenovoCath supplies, and if we hit our targets (including developing or partnering for sales and marketing capabilities), we see the potential for near-term revenue in 2025. Importantly, with
Key Business Third Quarter and Recent Highlights:
- Commercialization efforts for the RenovoCath delivery system progressed in response to increasing demand from oncology and interventional radiology physicians indicating a need for improved, targeted delivery of diagnostic and/or therapeutic agents.
Notably, RenovoRx signed a new work order with its manufacturing partner Medical Murray to increase production of RenovoCath devices. With manufacturing arrangements in place, RenovoRx is presently considering its best course for RenovoCath marketing and sales activities, which could be done directly or via a commercial partner. RenovoCath is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. - RenovoRx expects its RenovoCath commercial strategy to potentially generate revenue in 2025.
- Promoted Robert Strasser to Vice President of R&D and Operations. Strasser is a highly experienced, results-oriented, strategic business leader with a proven track record in operations and product commercialization management with prior roles at Cordis (Johnson & Johnson) and Boston Scientific. Strasser has served as RenovoRx’s Senior Director of R&D and Operations since October 2022, the same year he started managing RenovoRx’s relationship with Medical Murray.
- Enrolled the first patient at the University of Nebraska Medical Center (UNMC) for the ongoing pivotal Phase III TIGeR-PaC clinical trial. UNMC is the most recent clinical site to join TIGeR-PaC clinical study. UNMC is expected to drive enrollment of the TIGeR-PaC trial to completion in 2025 due to the large number of pancreatic patients they treat.
- Announced the publication of positive early-stage clinical data in an international peer-reviewed journal, The Oncologist®. The article titled “Treatment of Locally Advanced Pancreatic Cancer (LAPC) Using Localized Trans-Arterial Micro Perfusion (TAMP) of Gemcitabine: Combined Analysis of RR1 and RR2,” is a publication of early-stage clinical data, primarily procedure safety, overall survival (OS), and evaluation of factors associated with OS, in LAPC patients undergoing TAMP from the foundational studies conducted by RenovoRx.
Financial Highlights for Third Quarter ended September 30, 2024 (unaudited):
- Cash Position: Cash and cash equivalents as of September 30, 2024, were
$9.6 million . - R&D Expenses: Research and development expenses were approximately
$1.7 million for the three months ended September 30, 2024, remaining flat compared to the same period last year. Employee and related benefit costs increased$0.1 million including additional increase in clinical conferences and trade shows of$0.1 million . These increases were partially offset by lower regulatory and clinical consulting costs and manufacturing for our proprietary catheter delivery device. We anticipate research and development expenses to increase as we increase manufacturing costs for our device and continue advancing our Phase III clinical trial study throughout the remainder of the year. - G&A Expenses: General and administrative expenses were approximately
$1.2 million for the three months ended September 30, 2024, a decrease of approximately$0.2 million compared to approximately$1.4 million for the same period last year. The decrease was primarily due to decreases of$0.2 million in professional and consulting fees, and legal fees, partially offset by an increase of$0.1 million in investor and public relations costs. We anticipate general and administrative expenses increasing moderately throughout the remaining year as we progress our commercialization activities for our RenovoCath device. - Net Loss: Net loss was
$2.5 million for the quarter ended September 30, 2024, compared to net loss of$1.4 million for the quarter ended September 30, 2023. The decrease is primarily due to a decrease of$1.3 million in the fair value of common warrants issued under our Registered Direct Offering in April 2023 and an increase in interest and dividend income of$0.1 million . - Shares Outstanding: Shares of common stock outstanding, as of November 7, 2024, were 24,001,339.
About RenovoCath
Based on its FDA clearance, RenovoCath® is intended for the isolation of blood flow and delivery of fluids, including diagnostic and/or therapeutic agents, to selected sites in the peripheral vascular system. RenovoCath is also indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. For further information regarding our RenovoCath Instructions for Use (“IFU”), please see: IFU-10004-Rev.-F-Universal-IFU.pdf.
About the TIGeR-PaC Clinical Trial
TIGeR-PaC is an ongoing Phase III randomized multi-center study evaluating the proprietary TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of Locally Advanced Pancreatic Cancer (LAPC.) RenovoRx’s first product candidate using TAMP technology, is a novel investigational oncology drug-delivery combination utilizing the Company’s FDA-cleared RenovoCath® device for the intra-arterial administration of chemotherapy, gemcitabine.
The first interim analysis in the Phase III clinical trial was completed in March 2023, with the Data Monitoring Committee recommending a continuation of the study. The TIGeR-PaC study is investigating TAMP in LAPC. The study's primary endpoint is an overall survival benefit with secondary endpoints including reduced side effects versus standard of care. The second interim analysis for this study will be triggered by the 52nd event (i.e., patient death), which is estimated to occur in late 2024 or early 2025. The second interim data readout would follow thereafter, with the timing for such readout depending on customary factors such as time needed for analysis. RenovoRx is also aiming to complete patient enrollment in the TIGeR-PaC study in the first half of 2025.
About RenovoRx, Inc.
RenovoRx is a life sciences company developing novel targeted oncology therapies and offering RenovoCath®, a novel, U.S. Food and Drug Administration (FDA)-cleared local drug-delivery platform, targeting high unmet medical needs. RenovoRx’s patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform is designed to ensure precise therapeutic delivery across the arterial wall near the tumor site to bathe the target tumor, while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. RenovoRx’s novel approach to targeted treatment offers the potential for increased safety, tolerance, and improved efficacy, and its mission is to transform the lives of cancer patients by providing innovative solutions to enable targeted delivery of diagnostic and therapeutic agents.
RenovoRx’s Phase III lead product candidate is a novel oncology drug-device combination product. It is being investigated under a U.S. investigational new drug application that is regulated by the FDA’s 21 CFR 312 pathway. The investigational drug-device combination candidate utilizes RenovoCath, which is indicated for temporary vessel occlusion in applications including arteriography, preoperative occlusion, and chemotherapeutic drug infusion. The intra-arterial infusion of chemotherapy, gemcitabine, utilizing the RenovoCath catheter is currently being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research (the drug division of FDA).
RenovoRx is also actively exploring other commercialization strategies utilizing its TAMP technology and FDA-cleared RenovoCath delivery system as a stand-alone device. The intra-arterial infusion of gemcitabine by the RenovoCath catheter is currently under investigation and has not been approved for commercial sale. RenovoCath with gemcitabine received Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years of market exclusivity upon NDA approval by the FDA.
For more information, visit www.renovorx.com. Follow RenovoRx on Facebook, LinkedIn, and X.
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of the Company’s management made in connection therewith contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section 21E of the Securities Exchange Act of 1934, including but not limited to statements regarding (i) our clinical trials and studies, including the overall timing and timing for additional interim data readouts and completion of patient enrollment for our ongoing TIGeR-PaC Phase III clinical trial study in LAPC, (ii) the potential of RenovoCath® or TAMP™ as standalone commercial products and our commercialization plans in general, (iii) the potential for our product candidates to treat or provide clinically meaningful outcomes for certain medical conditions or diseases and (iii) our efforts to explore commercialization strategies utilizing our TAMP technology. Statements that are not purely historical are forward-looking statements. The forward-looking statements contained herein are based upon our current expectations and beliefs regarding future events, many of which, by their nature, are inherently uncertain, outside of our control and involve assumptions that may never materialize or may prove to be incorrect. These may include estimates, projections and statements relating to our research and development plans, intellectual property development, clinical trials, our therapy platform, business plans, financing plans, objectives and expected operating results, which are based on current expectations and assumptions that are subject to known and unknown risks and uncertainties that may cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These statements may be identified using words such as “may,” “expects,” “plans,” “aims,” “anticipates,” “believes,” “forecasts,” “estimates,” “intends,” and “potential,” or the negative of these terms or other comparable terminology regarding RenovoRx’s expectations strategy, plans or intentions, although not all forward-looking statements contain these words. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, that could cause actual events to differ materially from those projected or indicated by such statements, including, among other things: (i) the risk that our exploration of commercial opportunities for our TAMP technology may not lead to viable, revenue generating operations; (ii) circumstances which would adversely impact our ability to efficiently utilize our cash resources on hand or raise additional funding, (iii) the timing of the initiation, progress and potential results (including the results of interim analyses) of TIGeR-PaC and any other preclinical studies, clinical trials and our research programs; (iv) the possibility that interim results may not be predictive of the outcome of our clinical trials, which may not demonstrate sufficient safety and efficacy to support regulatory approval of our product candidate, (v) that the applicable regulatory authorities may disagree with our interpretation of the data; research and clinical development plans and timelines, and the regulatory process for our product candidates; (vi) future potential regulatory milestones for our product candidates, including those related to current and planned clinical studies; (vii) our ability to use and expand our therapy platform to build a pipeline of product candidates; (viii) our ability to advance product candidates into, and successfully complete, clinical trials; (ix) the timing or likelihood of regulatory filings and approvals; (x) our estimates of the number of patients who suffer from the diseases we are targeting and the number of patients that may enroll in our clinical trials; (xi) the commercialization potential of our product candidates, if approved; (xii) our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved; (xiii) future strategic arrangements and/or collaborations and the potential benefits of such arrangements; (xiv) our estimates regarding expenses, future revenue, capital requirements and needs for additional financing and our ability to obtain additional capital; (xv) the sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure requirements; (xvi) our ability to retain the continued service of our key personnel and to identify, and hire and retain additional qualified personnel; (xvii) the implementation of our strategic plans for our business and product candidates; (xviii) the scope of protection we are able to establish and maintain for intellectual property rights, including our therapy platform, product candidates and research programs; (xix) our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; (xx) the pricing, coverage and reimbursement of our product candidates, if approved; and (xxi) developments relating to our competitors and our industry, including competing product candidates and therapies. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that we file from time to time with the Securities and Exchange Commission.
Forward-looking statements included herein are made as of the date hereof, and RenovoRx does not undertake any obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as required by law.
Contact:
KCSA Strategic Communications
Valter Pinto or Jack Perkins
T:212-896-1254
RenovoRX@KCSA.com
FAQ
What was RenovoRx (RNXT) cash position in Q3 2024?
When does RenovoRx (RNXT) expect to generate revenue from RenovoCath?
What was RenovoRx's (RNXT) net loss in Q3 2024?
When is RenovoRx (RNXT) expecting to complete patient enrollment for TIGeR-PaC trial?
